Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Orthotopic editing of T-cell receptors.

Kortleve D, Hammerl D, Debets R.

Nat Biomed Eng. 2019 Dec;3(12):949-950. doi: 10.1038/s41551-019-0490-4. No abstract available.

PMID:
31811268
2.

Clonality, antigen recognition and suppression of CD8+ T cells differentially affect prognosis of breast cancer subtypes.

Hammerl D, Massink MPG, Smid M, van Deurzen CHM, Meijers-Heijboer HEJ, Waisfisz Q, Debets R, Martens JWM.

Clin Cancer Res. 2019 Oct 24. pii: clincanres.0285.2019. doi: 10.1158/1078-0432.CCR-19-0285. [Epub ahead of print]

PMID:
31649042
3.

Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens.

Weenink B, Draaisma K, Ooi HZ, Kros JM, Sillevis Smitt PAE, Debets R, French PJ.

Sci Rep. 2019 Oct 10;9(1):14643. doi: 10.1038/s41598-019-51063-6.

4.

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients.

Hurkmans DP, Basak EA, van Dijk T, Mercieca D, Schreurs MWJ, Wijkhuijs AJM, Bins S, Hoop EO, Debets R, Joerger M, Odink A, van der Veldt AAM, van der Leest CH, Aerts JGJV, Mathijssen RHJ, Koolen SLW.

J Immunother Cancer. 2019 Jul 19;7(1):192. doi: 10.1186/s40425-019-0669-y.

5.

Lack of B and T cell reactivity towards IDH1R132H in blood and tumor tissue from LGG patients.

Weenink B, van Brakel M, Wijers R, Sillevis Smitt PAE, French PJ, Debets R.

J Neurooncol. 2019 Aug;144(1):79-87. doi: 10.1007/s11060-019-03228-6. Epub 2019 Jun 25.

6.

CD45RA+CCR7- CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab.

Kunert A, Basak EA, Hurkmans DP, Balcioglu HE, Klaver Y, van Brakel M, Oostvogels AAM, Lamers CHJ, Bins S, Koolen SLW, van der Veldt AAM, Sleijfer S, Mathijssen RHJ, Aerts JGJV, Debets R.

J Immunother Cancer. 2019 Jun 8;7(1):149. doi: 10.1186/s40425-019-0608-y.

7.

Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response.

Saeed M, Zalba S, Seynhaeve ALB, Debets R, Ten Hagen TLM.

Int J Nanomedicine. 2019 Mar 26;14:2069-2089. doi: 10.2147/IJN.S190736. eCollection 2019.

8.

Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.

Basak EA, Koolen SLW, Hurkmans DP, Schreurs MWJ, Bins S, Oomen-de Hoop E, Wijkhuijs AJM, Besten ID, Sleijfer S, Debets R, van der Veldt AAM, Aerts JGJV, Mathijssen RHJ.

Eur J Cancer. 2019 Mar;109:12-20. doi: 10.1016/j.ejca.2018.12.008. Epub 2019 Jan 14.

PMID:
30654225
9.

Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies.

Hammerl D, Rieder D, Martens JWM, Trajanoski Z, Debets R.

Trends Immunol. 2018 Nov;39(11):921-936. doi: 10.1016/j.it.2018.09.004. Epub 2018 Oct 9. Review.

PMID:
30309702
10.

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.

de Goeje PL, Klaver Y, Kaijen-Lambers MEH, Langerak AW, Vroman H, Kunert A, Lamers CHJ, Aerts JGJV, Debets R, Hendriks RW.

Front Immunol. 2018 Sep 7;9:2034. doi: 10.3389/fimmu.2018.02034. eCollection 2018.

11.

Consumption of β-glucans to spice up T cell treatment of tumors: a review.

de Graaff P, Govers C, Wichers HJ, Debets R.

Expert Opin Biol Ther. 2018 Oct;18(10):1023-1040. doi: 10.1080/14712598.2018.1523392. Review.

PMID:
30221551
12.

Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.

van Duijn PW, Marques RB, Ziel-van der Made ACJ, van Zoggel HJAA, Aghai A, Berrevoets C, Debets R, Jenster G, Trapman J, van Weerden WM.

Prostate. 2018 Sep;78(13):1013-1023. doi: 10.1002/pros.23659. Epub 2018 May 29.

PMID:
30133757
13.

Epithelial-Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression.

Kolijn K, Verhoef EI, Smid M, Böttcher R, Jenster GW, Debets R, van Leenders GJLH.

Cancer Res. 2018 Aug 15;78(16):4671-4679. doi: 10.1158/0008-5472.CAN-17-3752. Epub 2018 Jun 19.

14.

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.

Bins S, Basak EA, El Bouazzaoui S, Koolen SLW, Oomen-de Hoop E, van der Leest CH, van der Veldt AAM, Sleijfer S, Debets R, van Schaik RHN, Aerts JGJV, Mathijssen RHJ.

Br J Cancer. 2018 May;118(10):1296-1301. doi: 10.1038/s41416-018-0074-1. Epub 2018 Apr 26.

15.

Engineering T cells for adoptive therapy: outsmarting the tumor.

Kunert A, Debets R.

Curr Opin Immunol. 2018 Apr;51:133-139. doi: 10.1016/j.coi.2018.03.014. Epub 2018 Mar 24. Review.

16.

Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?

Agahozo MC, Hammerl D, Debets R, Kok M, van Deurzen CHM.

Mod Pathol. 2018 Jul;31(7):1012-1025. doi: 10.1038/s41379-018-0030-x. Epub 2018 Feb 20. Review.

17.

T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression.

Mustafa DAM, Pedrosa RMSM, Smid M, van der Weiden M, de Weerd V, Nigg AL, Berrevoets C, Zeneyedpour L, Priego N, Valiente M, Luider TM, Debets R, Martens JWM, Foekens JA, Sieuwerts AM, Kros JM.

Acta Neuropathol. 2018 Apr;135(4):581-599. doi: 10.1007/s00401-018-1806-2. Epub 2018 Jan 19.

18.

Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors.

Kunert A, Chmielewski M, Wijers R, Berrevoets C, Abken H, Debets R.

Oncoimmunology. 2017 Oct 11;7(1):e1378842. doi: 10.1080/2162402X.2017.1378842. eCollection 2017.

19.

Breast cancer genomics and immuno-oncological markers to guide immune therapies.

Hammerl D, Smid M, Timmermans AM, Sleijfer S, Martens JWM, Debets R.

Semin Cancer Biol. 2018 Oct;52(Pt 2):178-188. doi: 10.1016/j.semcancer.2017.11.003. Epub 2017 Nov 6. Review.

20.

T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity Risk.

Kunert A, Obenaus M, Lamers CHJ, Blankenstein T, Debets R.

Clin Cancer Res. 2017 Oct 15;23(20):6012-6020. doi: 10.1158/1078-0432.CCR-17-1012. Epub 2017 Jun 23. Review.

21.

The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8+T Cell Anti-tumor Activity.

Kleijn A, van den Bossche W, Haefner ES, Belcaid Z, Burghoorn-Maas C, Kloezeman JJ, Pas SD, Leenstra S, Debets R, de Vrij J, Dirven CMF, Lamfers MLM.

Mol Ther Oncolytics. 2017 Mar 1;5:11-19. doi: 10.1016/j.omto.2017.02.002. eCollection 2017 Jun 16.

22.

Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities.

Van Caeneghem Y, De Munter S, Tieppo P, Goetgeluk G, Weening K, Verstichel G, Bonte S, Taghon T, Leclercq G, Kerre T, Debets R, Vermijlen D, Abken H, Vandekerckhove B.

Oncoimmunology. 2017 Jan 19;6(3):e1283460. doi: 10.1080/2162402X.2017.1283460. eCollection 2017.

23.

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients.

Klaver Y, van Steenbergen SC, Sleijfer S, Debets R, Lamers CH.

Front Immunol. 2016 Dec 26;7:648. doi: 10.3389/fimmu.2016.00648. eCollection 2016.

24.

T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors.

Manzo T, Sturmheit T, Basso V, Petrozziello E, Hess Michelini R, Riba M, Freschi M, Elia AR, Grioni M, Curnis F, Protti MP, Schumacher TN, Debets R, Swartz MA, Corti A, Bellone M, Mondino A.

Cancer Res. 2017 Feb 1;77(3):658-671. doi: 10.1158/0008-5472.CAN-16-0725. Epub 2016 Nov 21.

25.

CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation.

Lamers CH, Wijers R, van Bergen CA, Somers JA, Braakman E, Gratama JW, Debets R, Falkenburg JH, Cornelissen JJ.

Blood. 2016 Oct 27;128(17):2165-2174. Epub 2016 Aug 16.

PMID:
27531680
26.

Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.

Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJ, Vlugt-Daane MV, van Galen A, Nik-Zainal S, Staaf J, Brinkman AB, van de Vijver MJ, Richardson AL, Fatima A, Berentsen K, Butler A, Martin S, Davies HR, Debets R, Gelder ME, van Deurzen CH, MacGrogan G, Van den Eynden GG, Purdie C, Thompson AM, Caldas C, Span PN, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Ringnér M, Tommasi S, Eyford J, Broeks A, Vincent-Salomon A, Futreal PA, Knappskog S, King T, Thomas G, Viari A, Langerød A, Børresen-Dale AL, Birney E, Stunnenberg HG, Stratton M, Foekens JA, Martens JW.

Nat Commun. 2016 Sep 26;7:12910. doi: 10.1038/ncomms12910.

27.

Prostate Cancer and Immune Monitoring: Are We Heading Towards Better Selection of Patients and Treatment Strategies?

Lolkema M, Debets R, de Wit R.

Eur Urol. 2017 May;71(5):788-789. doi: 10.1016/j.eururo.2016.08.014. Epub 2016 Aug 17. No abstract available.

PMID:
27544581
28.

MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses.

Kunert A, van Brakel M, van Steenbergen-Langeveld S, da Silva M, Coulie PG, Lamers C, Sleijfer S, Debets R.

J Immunol. 2016 Sep 15;197(6):2541-52. doi: 10.4049/jimmunol.1502024. Epub 2016 Aug 3.

29.

Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells.

Klaver Y, van Steenbergen SCL, Sleijfer S, Debets R, Lamers CHJ.

Clin Immunol. 2016 Aug;169:107-113. doi: 10.1016/j.clim.2016.06.014. Epub 2016 Jul 1.

PMID:
27377533
30.

Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview.

Lamers CH, Klaver Y, Gratama JW, Sleijfer S, Debets R.

Biochem Soc Trans. 2016 Jun 15;44(3):951-9. doi: 10.1042/BST20160037.

PMID:
27284065
31.

Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient.

Siddiqui I, Erreni M, van Brakel M, Debets R, Allavena P.

J Immunother Cancer. 2016 Apr 19;4:21. doi: 10.1186/s40425-016-0125-1. eCollection 2016.

32.

Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody.

Saeed M, van Brakel M, Zalba S, Schooten E, Rens JA, Koning GA, Debets R, Ten Hagen TL.

Int J Nanomedicine. 2016 Mar 8;11:955-75. doi: 10.2147/IJN.S96123. eCollection 2016.

33.

TCR-engineered T cells to treat tumors: Seeing but not touching?

Debets R, Donnadieu E, Chouaib S, Coukos G.

Semin Immunol. 2016 Feb;28(1):10-21. doi: 10.1016/j.smim.2016.03.002. Epub 2016 Mar 17. Review.

PMID:
26997556
34.

IL-4 Downregulates IL-1β and IL-6 and Induces GATA3 in Psoriatic Epidermal Cells: Route of Action of a Th2 Cytokine.

Onderdijk AJ, Baerveldt EM, Kurek D, Kant M, Florencia EF, Debets R, Prens EP.

J Immunol. 2015 Aug 15;195(4):1744-52. doi: 10.4049/jimmunol.1401740. Epub 2015 Jul 13.

35.

Adoptive T-cell therapy: a need for standard immune monitoring.

Klaver Y, Kunert A, Sleijfer S, Debets R, Lamers CH.

Immunotherapy. 2015;7(5):513-33. doi: 10.2217/imt.15.23. Review.

PMID:
26065477
36.

The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity.

Kleijn A, Kloezeman J, Treffers-Westerlaken E, Fulci G, Leenstra S, Dirven C, Debets R, Lamfers M.

Oncoimmunology. 2014 Dec 13;3(9):e955697. eCollection 2014 Oct.

37.

T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.

Lamers CH, van Steenbergen-Langeveld S, van Brakel M, Groot-van Ruijven CM, van Elzakker PM, van Krimpen B, Sleijfer S, Debets R.

Hum Gene Ther Methods. 2014 Dec;25(6):345-57. doi: 10.1089/hgtb.2014.051.

38.

Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Straetemans T, Berrevoets C, Coccoris M, Treffers-Westerlaken E, Wijers R, Cole DK, Dardalhon V, Sewell AK, Taylor N, Verweij J, Debets R.

Mol Ther. 2015 Feb;23(2):396-406. doi: 10.1038/mt.2014.215. Epub 2014 Nov 3.

39.

TCRs genetically linked to CD28 and CD3ε do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity.

Govers C, Sebestyén Z, Roszik J, van Brakel M, Berrevoets C, Szöőr Á, Panoutsopoulou K, Broertjes M, Van T, Vereb G, Szöllősi J, Debets R.

J Immunol. 2014 Nov 15;193(10):5315-26. doi: 10.4049/jimmunol.1302074. Epub 2014 Oct 15.

40.

Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma.

Balvers RK, Belcaid Z, van den Hengel SK, Kloezeman J, de Vrij J, Wakimoto H, Hoeben RC, Debets R, Leenstra S, Dirven C, Lamfers ML.

Viruses. 2014 Aug 12;6(8):3080-96. doi: 10.3390/v6083080.

41.

Can we increase the yield of FDG-PET in the preoperative work-up for epilepsy surgery?

van't Klooster MA, Huiskamp G, Zijlmans M, Debets RM, Comans EF, Bouvard S, Ryvlin P, Leijten FS.

Epilepsy Res. 2014 Aug;108(6):1095-105. doi: 10.1016/j.eplepsyres.2014.04.011. Epub 2014 May 13.

PMID:
24893829
42.

The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.

Kleijn A, Kloezeman J, Treffers-Westerlaken E, Fulci G, Leenstra S, Dirven C, Debets R, Lamfers M.

PLoS One. 2014 May 27;9(5):e97495. doi: 10.1371/journal.pone.0097495. eCollection 2014.

43.

Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell response.

Liu NQ, De Marchi T, Timmermans AM, Beekhof R, Trapman-Jansen AM, Foekens R, Look MP, van Deurzen CH, Span PN, Sweep FC, Brask JB, Timmermans-Wielenga V, Debets R, Martens JW, Foekens JA, Umar A.

Mol Cell Proteomics. 2014 Jul;13(7):1814-27. doi: 10.1074/mcp.M113.037176. Epub 2014 Apr 17.

44.

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu.

Kunert A, Straetemans T, Govers C, Lamers C, Mathijssen R, Sleijfer S, Debets R.

Front Immunol. 2013 Nov 8;4:363. doi: 10.3389/fimmu.2013.00363. eCollection 2013. Review.

45.

TCR-engineered T cells: a model of inducible TCR expression to dissect the interrelationship between two TCRs.

Reuß S, Sebestyén Z, Heinz N, Loew R, Baum C, Debets R, Uckert W.

Eur J Immunol. 2014 Jan;44(1):265-74. doi: 10.1002/eji.201343591. Epub 2013 Oct 20.

46.

An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8α Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT.

Schaft N, Coccoris M, Drexhage J, Knoop C, de Vries IJ, Adema GJ, Debets R.

Front Immunol. 2013 Sep 4;4:270. doi: 10.3389/fimmu.2013.00270. eCollection 2013.

47.

Genetically modified T lymphocytes: more than just direct effectors.

Lamers CH, Debets R.

Immunotherapy. 2013 Jul;5(7):691-4. doi: 10.2217/imt.13.62.

PMID:
23829619
48.

Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R, Gratama JW.

Mol Ther. 2013 Apr;21(4):904-12. doi: 10.1038/mt.2013.17. Epub 2013 Feb 19.

49.

Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells.

Lamers CH, van Elzakker P, van Steenbergen SC, Luider BA, Groot C, van Krimpen BA, Vulto A, Sleijfer S, Debets R, Gratama JW.

Cytotherapy. 2013 May;15(5):620-6. doi: 10.1016/j.jcyt.2012.12.006. Epub 2013 Feb 4.

PMID:
23388583
50.

Chimeric antigen receptors for T-cell based therapy.

Cheadle EJ, Sheard V, Hombach AA, Chmielewski M, Riet T, Berrevoets C, Schooten E, Lamers C, Abken H, Debets R, Gilham DE.

Methods Mol Biol. 2012;907:645-66. doi: 10.1007/978-1-61779-974-7_36.

PMID:
22907378

Supplemental Content

Loading ...
Support Center